CD22 and acute lymphoblastic leukemia: Inotuzumab ozogamicin is a conjugated antibody-drug (ADC) consisting of a monoclonal antibody (mAb) directed to CD22, an antigen present on the cancer cells of almost all patients with B-cell precursor ALL, linked to a cytotoxic agent.